TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04996784

Intervention type: OTHER
Intervention: Capillary blood sampling
Description: The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S\&S (Whatman).

Intervention type: OTHER
Intervention: Capillary blood sampling
Description: The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S\&S (Whatman).
Study: NCT06672458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Short Term Therapy
Description: Therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. Conventional therapy will consist of performance hand and finger dexterity tests as well as arm functional mobility tasks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove Long Term Therapy
Description: FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove Long Term Therapy
Description: FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove Long Term Therapy
Description: FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove Long Term Therapy
Description: FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.
Study: NCT05652101

Intervention type: OTHER
Intervention: collection of medical data
Description: The data collected concerns:~* Sex~* Age~* Socio-professional category of patients or parents / level of education of the parents~* Family history~* Neonatal patient data (pregnancy, childbirth)~* Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~* Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~* Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~* Genetic data if available

Intervention type: OTHER
Intervention: Vineland Adaptive Behaviour Scales (VABS2) questionnaire
Description: This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose.
Study: NCT05796531

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Evaluative Conditioning
Description: Participants are told which pictures are matched pairs. They find the matched pairs among 4 or 8 pictures. By associating pictures and words associated with SITB (e.g., pictures of cut skin, pictures of people engaging in potentially suicidal behaviors, and the word death) with naturally aversive images (e.g., snakes and spiders), it increases the aversion to SITB. The second goal is to increase liking toward the self by pairing self-relevant stimuli (e.g., the participant's name or other self-relevant details, as well as words like I and me).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral comparison condition
Description: Match neutral pictures to account for doing an intervention.
Study: NCT06365931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation
Description: Patients will receive a needle circuit approaching the deep peroneal nerve in an echoguided manner. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
Study: NCT06347419

Intervention type: OTHER
Intervention: Physiotherapy evaluation
Description: In the physiotherapy evaluation, patients' spinal stability, rotary stability, and body awareness will be assessed.
Study: NCT06365931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromodulation
Description: Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-percutaneous
Description: Patients will have the neuromodulation circuit placed with needles at 0 intensity, approaching the deep peroneal nerve in an ultrasound-guided manner.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-transcutaneous
Description: patients will have the electrodes placed over the tibialis anterior muscle at intensity 0.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)
Description: Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)
Description: Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)
Description: Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)
Description: Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.
Study: NCT05969782

Intervention type: DEVICE
Intervention: EVAR
Description: Endovascular repair of aortoiliac aneurysm using Zenith or Endurant

Intervention type: DEVICE
Intervention: EVAR
Description: Endovascular repair of aortoiliac aneurysm using Zenith or Endurant
Study: NCT06673550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Description: Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Description: Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Description: Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.
Study: NCT04656171

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI of the hand and forearm,
Description: MRI of the hand and forearm,

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI of the hand and forearm,
Description: MRI of the hand and forearm,
Study: NCT04127682

Intervention type: OTHER
Intervention: Antibiotic KAP questionnaire
Description: • Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
Study: NCT05481554

Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.

Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
Study: NCT05044637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
Study: NCT04713228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTSENS Pen
Description: ARTerial Stiffness Evaluation for Noninvasive Screening

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTSENS Pen
Description: ARTerial Stiffness Evaluation for Noninvasive Screening
Study: NCT06158633

Intervention type: DRUG
Intervention: Prevora
Description: Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months.
Study: NCT04713228

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARTSENS Pen
Description: ARTerial Stiffness Evaluation for Noninvasive Screening
Study: NCT06529276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality clinical learning
Description: Clinical learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation, using augmented reality immersive learning technology.
Study: NCT05153837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline intravenous administration
Description: Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral water
Description: 500 ml oral water
Study: NCT05077267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 100ug
Description: IM injection 100ug dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 100ug
Description: IM injection 100ug dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 50ug
Description: IM injection 50ug dose
Study: NCT06529276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm regular clinical learning
Description: Regular bedside learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation,
Study: NCT05734859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolyzed Alkaline Ionizer
Description: Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
Study: NCT06036537

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosis of Interstitial lung disease
Description: Serum marker detection，High resolution computed tomography scan
Study: NCT06696066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRS Program
Description: The PRS program will be delivered by a certified recovery specialist (CRS) over the course of 6-months. The CRS will provide supportive care to the participant during their initial 6-months of MOUD treatment to increase patient engagement in their treatment. The CRS may provide emotional support; help participants to identify their recovery assets, goals, and barriers; guide participants in creating a recovery plan; help participants to increase their coping skills; and assist participants in connecting to community and recovery resources.
Study: NCT06701396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT06700421

Intervention type: DRUG
Group type: OTHER
Intervention: Adebrelimab + Apatinib
Description: Adebrelimab combined with apatinib

Intervention type: DRUG
Group type: OTHER
Intervention: Adebrelimab + Apatinib
Description: Adebrelimab combined with apatinib
Study: NCT06700798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: 150mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375mg/m\^2, intravenous
Study: NCT03697343

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiosurgery
Description: Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
Study: NCT06700798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375mg/m\^2, intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: 60mg/m\^2
Study: NCT06701604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single Strain Probiotic + Milk Protein
Description: • Both conditions matched flavor, color, and serving size

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Milk Protein
Description: • Both conditions matched flavor, color, and serving size
Study: NCT06701188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Coaching
Description: The intervention group will receive Virtual coaching: a) tailored weekly coaching through text messages with a weekly summary of progress and tailored messages on goals based on self-reported exercise through the app, barriers, and self-management of PA. b) Individual, tailored monthly coaching will be delivered by the exercise physiologist via video or phone meetings with a focus on self-efficacy building, problem-solving skills, and relapse.
Study: NCT06703866

Intervention type: OTHER
Intervention: Non Small Cell Lung Cancer (NSCLC)
Description: Application of value based medicine predictive model
Study: NCT06703073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A: vilobelimab
Description: Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort A: placebo
Description: Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B: paridiprubart
Description: Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort B: placebo
Description: Administered as a single IV dose of placebo on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort C: bevacizumab
Description: Administered as a single IV dose of 500 mg on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort C: placebo
Description: Administered as a single IV dose of placebo on Day 1
Study: NCT06704009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-101 0.05 mM
Description: Low concentration of NT-101 (0.05 mM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-101 0.2 mM
Description: High concentration of NT-101 (0.2 mM)
Study: NCT06301477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: 7.5g/m2 or 5.0g/m2 (body surface area) resistant starch oral consumption

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral consumption of food-grade cornstarch
Study: NCT06425146

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cytobrush sample
Description: Healthy oral mucosa will be collected using a cytobrush, which is a minimally invasive method for patients

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling (6 mL), taken from a routine biological exam
Study: NCT03904498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study: NCT04136626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perspectives OCD
Description: The app-delivered cognitive behavioral therapy (CBT) in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Health and Well-Being Program
Description: The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
Study: NCT04648774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane (SAP) block
Description: With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
Study: NCT06144827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiparametric MRI scans
Description: Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI scans
Description: Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI scans + HepQuantShunt Test
Description: Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
Study: NCT05346237

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaire
Description: Filling out questionnaires, measuring maximum phonation and diadochokinesis